PTLA reports top-line phase-2 data for PRT4445 as Eliquis antidote: http://finance.yahoo.com/news/portola-announces-factor-xa-inhibitor-120000977.html Analysis of anticoagulation markers and plasma concentration levels of Eliquis in blood samples taken from the subjects indicates that PRT4445 produces a rapid, sustained and dose-related reversal of the anticoagulant activity of Eliquis. In addition, no serious adverse events were reported. Additional details will be presented at an upcoming medical conference. These data are well-timed vis-à-vis PTLA’s plans to IPO.